Research Progress of HER2 Gene Mutation in Treatment of Breast Cancer

MENG Wenjing; TONG Zhongsheng

doi:10.3971/j.issn.1000-8578.2023.22.0769

Zhongliu Fangzhi Yanjiu (Feb 2023)

Research Progress of HER2 Gene Mutation in Treatment of Breast Cancer

MENG Wenjing,
TONG Zhongsheng

Affiliations

MENG Wenjing: Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy and Key Laboratory of Cancer Prevention and Therapy (Ministry of Education), Tianjin 300060, China
TONG Zhongsheng: Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy and Key Laboratory of Cancer Prevention and Therapy (Ministry of Education), Tianjin 300060, China

DOI: https://doi.org/10.3971/j.issn.1000-8578.2023.22.0769
Journal volume & issue: Vol. 50, no. 2
pp. 191 – 194

Abstract

Read online

HER2 is a tyrosine kinase receptor. It is the main drug target and clinical biomarker for the treatment of breast cancer. About 2% of breast cancer cases has HER2 mutations. Regardless of the expression level or amplification status of HER2, breast cancer with HER2 mutations may respond to targeted HER2 therapy. This article reviews the research progress of HER2 gene mutation in the treatment of breast cancer.

Published in Zhongliu Fangzhi Yanjiu

ISSN: 1000-8578 (Print)
Publisher: Magazine House of Cancer Research on Prevention and Treatment
Country of publisher: China
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.zlfzyj.com

About the journal

Abstract

Keywords